Emerging erythropoiesis-stimulating agents
- 23 February 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Nephrology
- Vol. 6 (4), 218-223
- https://doi.org/10.1038/nrneph.2010.19
Abstract
The stimulation of erythropoiesis is a rapidly evolving area of research, with mechanistic insights often developing rapidly into therapeutic agents. A broad range of erythropoiesis-stimulating agents are currently in clinical use and many more under development are likely to enter the marketplace in the near future. To date, much of the investigative activity in this field has targeted activation of the erythropoietin receptor and factors that modulate hypoxia-related pathways of erythropoietin production within cells. This Review discusses newer erythropoiesis-stimulating agents currently under assessment for the treatment of anemia in patients with chronic kidney disease. Such agents include proteins and peptides that activate erythropoietin receptors, non-protein agents, and strategies with targets other than erythropoietin receptors.Keywords
This publication has 68 references indexed in Scilit:
- Erythropoiesis-Stimulating Agents — Time for a ReevaluationNew England Journal of Medicine, 2010
- Epoetin‐associated pure red cell aplasia: past, present, and future considerationsTransfusion, 2008
- Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III studyNephrology Dialysis Transplantation, 2008
- A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney diseaseCurrent Medical Research and Opinion, 2008
- C.E.R.A. Corrects Anemia in Patients with Chronic Kidney Disease not on DialysisClinical Journal of the American Society of Nephrology, 2008
- The first human cell line-derived erythropoietin, epoetin-? (Dynepo®), in the management of anemia in patients with chronic kidney diseaseClinical Nephrology, 2007
- An Extended Terminal Half-Life for Darbepoetin AlfaClinical Pharmacokinetics, 2006
- Erythropoietin receptors: their role beyond erythropoiesisNephrology Dialysis Transplantation, 2005
- Pure Red-Cell Aplasia and Epoetin TherapyNew England Journal of Medicine, 2004
- Differentiating Factors Between Erythropoiesis-Stimulating AgentsDrugs, 2004